Investigational apitegromab met its primary endpoint of motor function improvement in a phase III trial of spinal muscular atrophy, Scholar Rock announced. Masked tapering with a targeted behavioral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback